MP18-12 DIFFUSION WEIGHTED IMAGING: DIFFERENTIATION OF CLEAR CELL FROM PAPILLARY RENAL CELL CARCINOMA

Background Whole-body diffusion-weighted imaging (DWI) has been widely used in detecting malignant metastases, including pulmonary metastases. Purpose To evaluate the possible utility of whole-body DWI in detecting pulmonary metastases of patients with clear cell renal cell carcinoma (ccRCC) and compare the exact differences between MR and CT in detecting pulmonary lesions. Material and Methods Whole-body DWI and chest CT examinations were performed on nine consecutive patients (8 men and 1 woman) with histologically confirmed ccRCC and possible metastatic lesions before chemotherapy. Results CT and MR demonstrated pulmonary metastases in seven patients and no metastatic lesions in two patients. The numbers of pulmonary metastases detected on CT, DWI-only, T1WI-only and DWI in combination with T1WI were 83, 35, 34 and 39, respectively. Metastases with a diameter above 1.0 cm could all be detected by DWI and a diameter above 0.7 cm could all be detected by DWI in combination with T1WI. Significant differences were obtained both for correlationship between diameter and detection rates of DWI and T1WI by using Spearman rank correlation analysis. Conclusion Although MR cannot be considered a replacement for CT in pulmonary metastases from ccRCC, whole-body DWI, with the combination of T1 dual echo, might be helpful for the evaluation of tumor response to chemotherapy in the follow-up of patients when the diameter of the pulmonary metastases is over 1.0 cm.

Download Full-text

Clear cell (Tubulo) papillary renal cell carcinoma: Case report

10.26226/morressier.578f37fbd462b8028d8904a2 ◽

2016 ◽

Author(s):

Ulku Kazanci

Keyword(s):

Renal Cell Carcinoma ◽

Case Report ◽

Cell Carcinoma ◽

Renal Cell ◽

Clear Cell ◽

Papillary Renal Cell Carcinoma ◽

Renal Cell Carcinoma Case

Download Full-text

Re: Stanley Weng, Renzo G. DiNatale, Andrew Silagy, et al. The Clinicopathologic and Molecular Landscape of Clear Cell Papillary Renal Cell Carcinoma: Implications in Diagnosis and Management. Eur Urol 2021;79:468–77

European Urology ◽

10.1016/j.eururo.2021.05.011 ◽

2021 ◽

Author(s):

Sounak Gupta ◽

Beth A. Pitel ◽

Shannon M. Knight ◽

Kevin C. Halling ◽

Rafael E. Jimenez ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Renal Cell ◽

Clear Cell ◽

Papillary Renal Cell Carcinoma ◽

Diagnosis And Management ◽

Molecular Landscape

Download Full-text

Mutation associated with Fanconi anemia pathway may increase patients’ second primary malignancy risk: Results from somatic and germline testing of clear cell papillary renal cell carcinoma

European Urology ◽

10.1016/s0302-2838(21)01088-5 ◽

2021 ◽

Vol 79 ◽

pp. S980

Author(s):

X. Tian ◽

A. Aihetaimujiang ◽

Y.Y. Qu ◽

H.L. Zhang ◽

D.W. Ye

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Fanconi Anemia ◽

Renal Cell ◽

Clear Cell ◽

Papillary Renal Cell Carcinoma ◽

Second Primary ◽

Second Primary Malignancy ◽

Primary Malignancy ◽

Germline Testing

Download Full-text

Down-regulation of BCL2L13 renders poor prognosis in clear cell and papillary renal cell carcinoma

Cancer Cell International ◽

10.1186/s12935-021-02039-y ◽

2021 ◽

Vol 21 (1) ◽

Author(s):

Fei Meng ◽

Luojin Zhang ◽

Mingjun Zhang ◽

Kaiqin Ye ◽

Wei Guo ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Kidney Cancer ◽

Renal Cell ◽

Poor Prognosis ◽

Clear Cell ◽

Papillary Renal Cell Carcinoma ◽

Functional Enrichment ◽

Cancer Tissue ◽

Down Regulation

Abstract Background BCL2L13 belongs to the BCL2 super family, with its protein product exhibits capacity of apoptosis-mediating in diversified cell lines. Previous studies have shown that BCL2L13 has functional consequence in several tumor types, including ALL and GBM, however, its function in kidney cancer remains as yet unclearly. Methods Multiple web-based portals were employed to analyze the effect of BCL2L13 in kidney cancer using the data from TCGA database. Functional enrichment analysis and hubs of BCL2L13 co-expressed genes in clear cell renal cell carcinoma (ccRCC) and papillary renal cell carcinoma (pRCC) were carried out on Cytoscape. Evaluation of BCL2L13 protein level was accomplished through immunohistochemistry on paraffin embedded renal cancer tissue sections. Western blotting and flow cytometry were implemented to further analyze the pro-apoptotic function of BCL2L13 in ccRCC cell line 786-0. Results BCL2L13 expression is significantly decreased in ccRCC and pRCC patients, however, mutations and copy number alterations are rarely observed. The poor prognosis of ccRCC that derived from down-regulated BCL2L13 is independent of patients’ gender or tumor grade. Furthermore, BCL2L13 only weakly correlates with the genes that mutated in kidney cancer or the genes that associated with inherited kidney cancer predisposing syndrome, while actively correlates with SLC25A4. As a downstream effector of BCL2L13 in its pro-apoptotic pathway, SLC25A4 is found as one of the hub genes that involved in the physiological function of BCL2L13 in kidney cancer tissues. Conclusions Down-regulation of BCL2L13 renders poor prognosis in ccRCC and pRCC. This disadvantageous factor is independent of any well-known kidney cancer related genes, so BCL2L13 can be used as an effective indicator for prognostic evaluation of renal cell carcinoma.

Download Full-text